BAY-293

BAY‑293 is a potent and selective small molecule inhibitor that disrupts the interaction between KRAS (a RAS GTPase oncogene product frequently mutated in cancer) and its guanine nucleotide exchange factor Son of Sevenless homolog 1 (SOS1). By blocking this protein-protein interaction (IC50 = 21 nM), BAY‑293 inhibits activation of RAS signaling and downstream pathways such as RAF-MEK‑ERK. This results in downregulation of active RAS in tumor cells and antiproliferative effects. It has shown synergistic activity with KRAS G12C inhibitors in preclinical models. Developed by Bayer for research purposes, it is widely used as a tool compound to study KRAS/SOS1 modulation in proliferative diseases including various cancers[1][3][7].

Other names

(R)-6,7-dimethoxy-2-methyl-N-(1-(4-(2-((methylamino)methyl)phenyl)thiophen-2-yl)ethyl)quinazolin-4-amine6,7-dimethoxy-2-methyl-N-(1-(4-(2-((methylamino)methyl)phenyl)thiophen-2-yl)ethyl)quinazolin-4-amine